Experimental HCV Drugs
Experimental HCV Drugs
AbbVie Combo Cures 96% of Treatment-experienced Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 18 December 2013 00:00
- Written by AbbVie
A 4-drug regimen containing 3 AbbVie direct-acting antivirals plus ribavirin produced sustained virological response in 96% of chronic hepatitis C patients without cirrhosis who were previously treated unsuccessfully with pegylated interferon and ribavirin, with similar response rates for HCV genotypes 1a and 1b, the company announced.
FDA Approves Sofosbuvir (Sovaldi) for Hepatitis C Genotypes 1, 2, 3, and 4
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 09 December 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration on Friday approved the first hepatitis C virus (HCV) polymerase inhibitor, sofosbuvir, to be marketed by Gilead Sciences under the brand name Sovaldi. Sofosbuvir was approved for use with ribavirin for people with HCV genotypes 2 or 3 -- making it the first-ever interferon-free hepatitis C treatment -- and in combination with pegylated interferon/ribavirin for people with harder-to-treat HCV genotypes 1 or 4.
AASLD 2013: MK-5172 + Ribavirin Works Well for People with Hepatitis C Genotype 1b
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 04 December 2013 00:00
- Written by Liz Highleyman
An interferon-free regimen consisting of Merck's next-generation hepatitis C virus (HCV) protease inhibitor MK-5172 plus ribavirin led to high rates of viral suppression and promising early cure rates for patients with HCV subtype 1b, according to a poster presented at the 64thAASLD Liver Meeting last month in Washington, DC.
Sofosbuvir/Ledipasvir Cures More than 90% of Genotype 1 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 09 December 2013 00:00
- Written by Gilead Sciences
Gilead Sciences this week announced sustained virological response rates from the Phase 3 ION trials testing a combination pill containing its newly approved HCV polymerase inhibitor sofosbuvir (Sovaldi) plus the NS5A inhibitor ledipasvir. Across the 3 studies, sofosbuvir/ledipasvir taken for 8 or 12 weeks cured more than 90% of treatment-naive and treatment-experienced genotype 1 patients.
AASLD 2013: Sofosbuvir + Ribavirin Effective Against Hepatitis C Genotype 4
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 04 December 2013 00:00
- Written by Liz Highleyman
A dual oral regimen of sofosbuvir plus ribavirin taken for 24 weeks led to an early cure at 4 weeks post-treatment for difficult-to-treat patients with hepatitis C virus (HCV) genotype 4, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC.
More Articles...
- AASLD 2013: Faldaprevir Triple Therapy Effective Across Patient Subgroups
- FDA Approves Simeprevir (Olysio) for Chronic Hepatitis C
- AASLD 2013: Faldaprevir All-oral Regimen Shows 100% Early Sustained Response for HCV 1a
- AbbVie All-Oral Regimen Produces 96% Cure Rate, Effective Against Both HCV 1a and 1b
Web Design and Development by